tetano
Editor, Senior Moderator
J Med Virol
. 2021 Dec 15.
doi: 10.1002/jmv.27527. Online ahead of print.
Outcome of COVID 19 in patients with chronic myeloid leukaemia: a single centre UK experience
George Nesr[SUP] 1 [/SUP], Zahbia Saleem[SUP] 1 [/SUP], Siamak Arami[SUP] 1 [/SUP]
Affiliations
Abstract
Chronic phase chronic myeloid leukaemia (CP-CML) patients receiving tyrosine kinase inhibitors (TKI) with COVID-19 have a favourable outcome as compared to those with other haematological malignancies. We reported the outcome 9 CP-CML patients with COVID-19 and showed modest need for inpatient management and mortality. TKI therapy whilst COVID-19 positive did not appear to worsen the outcome This article is protected by copyright. All rights reserved.
Keywords: Blood; Chemotherapy; Disease control; Epidemiology; SARS coronavirus; Virus classification.
. 2021 Dec 15.
doi: 10.1002/jmv.27527. Online ahead of print.
Outcome of COVID 19 in patients with chronic myeloid leukaemia: a single centre UK experience
George Nesr[SUP] 1 [/SUP], Zahbia Saleem[SUP] 1 [/SUP], Siamak Arami[SUP] 1 [/SUP]
Affiliations
- PMID: 34914847
- DOI: 10.1002/jmv.27527
Abstract
Chronic phase chronic myeloid leukaemia (CP-CML) patients receiving tyrosine kinase inhibitors (TKI) with COVID-19 have a favourable outcome as compared to those with other haematological malignancies. We reported the outcome 9 CP-CML patients with COVID-19 and showed modest need for inpatient management and mortality. TKI therapy whilst COVID-19 positive did not appear to worsen the outcome This article is protected by copyright. All rights reserved.
Keywords: Blood; Chemotherapy; Disease control; Epidemiology; SARS coronavirus; Virus classification.